國家衛生研究院 NHRI:Item 3990099045/9210
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 858839      在线人数 : 815
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9210


    题名: Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad
    作者: Denlinger, CS;Sym, SJ;Bendell, JC;Alsina, M;Watkins, D;Chao, Y;Cubillo, A;Kunz, PL;Sun, WJ;Baeksgaard, L;Chen, LT;Horgan, K;Frye, S;Kudia, AJ;McDonagh, CF;Czibere, AG;Moyo, VM;Chibaudel, B;Bang, YJ
    贡献者: National Institute of Cancer Research
    摘要: Background: HER2 overexpression occurs in ≤ 20% of GE cancers, and front-line fluoropyrimidine/platinum with TRAS increases survival in HER2+ GE junction/gastric cancer patients. Weekly PTX has activity after front-line therapy in GE cancers. HER3 is overexpressed in < 87% of GE cancers and expression is associated with poor prognosis. HER3 is activated by its ligand, heregulin, to form a potent signaling heterodimer with HER2 and is emerging as a key tumorigenic node and mediator of drug resistance. MM-111 is a novel molecule that inhibits heregulin-activated HER3 signaling in HER2+ tumors. In preclinical gastric cancer models, MM-111 potentiates the antitumor activity of TRAS and PTX, and also mitigates HER3-mediated resistance. MM-111 has been combined with PTX and TRAS in a multi-arm, dose escalation phase 1 trial. Most common dose-limiting toxicities include myelosuppression, GI toxicities, and electrolyte abnormalities. Methods: This is a randomized open-label multi-center Phase 2 study of PTX and TRAS +/- MM-111 in patients with HER2 expressing advanced GE adenocarcinoma. Arms are stratified for prior TRAS exposure, geographic region, and ECOG performance status. Patients are dosed with PTX at 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle; TRAS at 4 mg/kg loading dose then 2 mg/kg/weekly and MM-111 at 20 mg/kg/weekly. Pretreatment tumor biopsies and archived tumor tissue will be collected to explore the correlation of biomarkers associated with HER2, HER3 and heregulin signaling activity (1) between archived and pretreatment samples and (2) with clinical response. The primary objective is progression-free survival. Secondary objectives are overall survival, time to treatment failure, objective response rate, duration of response, safety, and health-related quality of life. Pharmacokinetic and immunogenicity analysis of MM-111 will be performed. Enrollment is ongoing.
    日期: 2014-05
    關聯: Journal of Clinical Oncology. 2014 May;32(15, Suppl.):TPS4148.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS4148
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000358613202097
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000358613202097.pdf61KbAdobe PDF303检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈